CSF1R and glioblastoma: Sotuletinib (BLZ945) is a brain-penetrant, oral CSF1R inhibitor that has demonstrated a reduction in TAM recruitment, tumour growth, and resistance to programmed cell death 1 (PD-1) inhibitors in animal models of intracranial glioblastoma multiforme (GBM).